Chicago Partners Investment Group LLC Purchases Shares of 1,836 Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Chicago Partners Investment Group LLC purchased a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 1,836 shares of the company's stock, valued at approximately $255,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Brooklyn Investment Group raised its holdings in shares of Neurocrine Biosciences by 99.1% in the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company's stock valued at $32,000 after acquiring an additional 115 shares in the last quarter. Blue Trust Inc. raised its holdings in shares of Neurocrine Biosciences by 171.9% during the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company's stock valued at $40,000 after buying an additional 220 shares in the last quarter. R Squared Ltd purchased a new position in shares of Neurocrine Biosciences during the 4th quarter valued at about $61,000. UMB Bank n.a. raised its holdings in shares of Neurocrine Biosciences by 211.6% during the 4th quarter. UMB Bank n.a. now owns 455 shares of the company's stock valued at $62,000 after buying an additional 309 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB raised its holdings in shares of Neurocrine Biosciences by 42.0% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 531 shares of the company's stock valued at $72,000 after buying an additional 157 shares in the last quarter. Hedge funds and other institutional investors own 92.59% of the company's stock.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ NBIX traded down $27.89 during mid-day trading on Friday, hitting $122.62. 6,519,519 shares of the stock traded hands, compared to its average volume of 952,604. The stock has a fifty day moving average price of $138.81 and a 200-day moving average price of $131.62. The company has a market cap of $12.42 billion, a price-to-earnings ratio of 37.27 and a beta of 0.33. Neurocrine Biosciences, Inc. has a 52 week low of $110.95 and a 52 week high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.45%. As a group, sell-side analysts predict that Neurocrine Biosciences, Inc. will post 6.53 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on NBIX shares. Barclays raised their price objective on Neurocrine Biosciences from $160.00 to $165.00 and gave the company an "overweight" rating in a report on Monday, December 23rd. William Blair reissued an "outperform" rating on shares of Neurocrine Biosciences in a report on Friday. Piper Sandler reissued an "overweight" rating and set a $160.00 price objective on shares of Neurocrine Biosciences in a report on Monday, December 23rd. Wedbush decreased their price objective on Neurocrine Biosciences from $157.00 to $147.00 and set an "outperform" rating on the stock in a report on Friday. Finally, UBS Group raised their price target on Neurocrine Biosciences from $162.00 to $176.00 and gave the stock a "buy" rating in a research report on Thursday, January 30th. Five investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $167.81.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, CEO Kyle Gano sold 65,000 shares of the company's stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $141.50, for a total value of $9,197,500.00. Following the completion of the sale, the chief executive officer now owns 135,392 shares in the company, valued at $19,157,968. This represents a 32.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Ingrid Delaet sold 623 shares of the company's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $149.29, for a total value of $93,007.67. Following the completion of the sale, the insider now owns 3,442 shares of the company's stock, valued at approximately $513,856.18. The trade was a 15.33 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 222,693 shares of company stock worth $32,718,279. 4.30% of the stock is owned by insiders.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.